Century Therapeutics (IPSC) just posted FY 2025 results that put revenue at US$109.2 million with basic EPS of US$0.51 for the latest half, against a trailing twelve month profile that still shows a loss, with EPS of US$0.11 and net income of US$9.6 million in the red on US$109.2 million of revenue. Over the past year, the company has reported revenue of US$1.6 million and EPS of US$0.82 in early 2024, then US$4.96 million with EPS of US$0.79 in the second half of 2024, and then the latest US$109.2 million of revenue with EPS of US$0.51. This path leaves margins front and center for how investors read this update against a still loss-making twelve month backdrop.

With the headline numbers on the table, the next step is to set them against the dominant stories around Century Therapeutics to see which narratives about growth potential and risk are reinforced and which start to look out of line.

Losses Narrow on a Trailing 12‑Month View

• On a trailing twelve month basis, Century Therapeutics reported US$109.2 million of revenue with a net loss of US$9.6 million, compared with a net loss of US$126.6 million on US$6.6 million of revenue in the prior half year included in that period.
• For a more optimistic, bullish style view, what stands out is that losses have been reduced at about 6.8% per year over the past five years. However, the latest trailing twelve month figures still show a net loss of US$9.6 million and basic EPS of US$0.11 in the red, which keeps the focus on how durable that loss reduction really is.

EPS Swings Between Halves Remain Wide

• Across the last three reported half year periods, basic EPS moved from a loss of US$0.82 in early 2024, to a loss of US$0.79 in the second half of 2024, then to a profit of US$0.51 in the first half of 2025, highlighting a wide range of outcomes across a short timeline.
• Bears argue that earnings are still fragile, and that view is supported by forecasts calling for earnings to decline by about 20.7% per year over the next three years, even after the swing to positive EPS in the latest half. This underlines how one profitable half does not yet offset a recent pattern of losses and the current trailing twelve month loss position.

P/S of 4.1x Sits Below Biotech Peers

• The current P/S ratio of 4.1x sits well below the 14x level for peers and the 12.2x average for the US Biotech industry, even though analysts expect Century Therapeutics to remain unprofitable over the next three years and have also forecast no revenue next year.
• For a more cautious, bearish narrative, what is striking is that the lower P/S multiple comes alongside substantial shareholder dilution over the past year and higher share price volatility in the last three months. Together, these factors suggest the market is weighing that valuation discount against a backdrop of continued forecast losses and no near term profitability in sight.

If you want to see how other investors are connecting these swings in revenue, EPS, and valuation, take a look at 📊 Read the what the Community is saying about Century Therapeutics.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Century Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Overall, does this seem more encouraging or more concerning to you? If you want to move quickly and decide for yourself, take a look at 1 key reward and 4 important warning signs.

See What Else Is Out There

Century Therapeutics still carries a trailing twelve month loss, wide EPS swings between halves, and analyst expectations that earnings may decline over the next few years.

If that mix of ongoing losses and earnings uncertainty feels a bit too volatile, you may want to quickly scan 68 resilient stocks with low risk scores that prioritise resilience and more predictable fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.